Biotech Values

[flatlander_60048]

I agree with the panic comment. 1st, the timing shows that the PR was released in an attempt to stem the sell off. 2nd, this appears no different than Teva's quick response to the m-enox on July 23, 2010 (i.e., that they anticipated approval for t-lovenox shortly). As previously discussed on this board, that PR was meant to create the inference that MNTA/Sandoz had not accomplished a difficult approval and that copaxone would require a much tougher approval. This was an attempt to undermine the competitions capabilities by indicating, big deal we will also have approval shortly.

Teva has also put out long term guidance which cannot be met without another 2-3 years dominance in the MS market. This looks much more fragile after yesterday. IMHO this does suggest that Teva is quick to roll out damage control PR's.

FL